Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
F. Urfali (Sakarya, Turkey), S. Metintas (Eskisehir, Turkey), A. Gurgen (Erzurum, Turkey), G. Ak (Eskisehir, Turkey), R. Ozkan (Manisa, Turkey), M. Metintas (Eskisehir, Turkey). Evaluation of chemotherapy response determined by volumetric method in malignant pleural mesothelioma and its effect on determination to survival. 2893

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Three dimensional evaluation of chemotherapy response in malign pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 754s Year: 2007 Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Source: Eur Respir J 2011; 37: 162-168 Year: 2011 Breath analysis allows to predict treatment response in malignant pleural mesothelioma patients. Source: Virtual Congress 2021 – Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease Year: 2021 Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma Source: Eur Respir J , 49 (3) 1601428; DOI: 10.1183/13993003.01428-2016 Year: 2017 PET predicts survival in malignant pleural mesothelioma Source: ISSN=ISSN 1810-6838, ISBN=, page=290 Year: 2007 Malignant mesothelioma and chemotherapy: efficacy and influence on survival of patients Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 Clinical usefulness of the novel drug sensitivity test for malignancy using pleural effusion Source: Annual Congress 2006 - Lung cancer biology and chemosensitivity Year: 2006 Relationship between baseline metabolic 18F-FDG parameters and survival in malignant pleural mesothelioma: A single centre experience Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Comparison between treatment with IL2, and IL2 in combination with chemotherapy in malignant pleural mesothelioma Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients Source: Eur Respir J 2011; 38: 1425-1430 Year: 2011 Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007 Second-line chemotherapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002 Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018